Ilyang Pharmaceutical Co.,Ltd
007575.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$162.13B
Close$
$-2977.12
139.8% downside
Current Fair Value
139.8% downsideOvervalued by 139.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $162.13 Billion |
|---|---|
| Enterprise Value | $252.94 Billion |
| Dividend Yield | $180.00 (1.95%) |
| Earnings per Share | $375.42 |
| Beta | 0.43 |
| Outstanding Shares | 16,853,000 |
Return
| Return on Equity | 6.82% |
|---|---|
| Return on Assets | 3.83% |
| Return on Invested Capital | -13.25% |
Valuation & Multiples
| P/E Ratio | 7.86 |
|---|---|
| PEG | -1.58 |
| Price to Sales | 0.45 |
| Price to Book Ratio | 0.49 |
| Enterprise Value to Revenue | 0.91 |
| Enterprise Value to EBIT | -6.43 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.41 |
| Debt to Equity | 0.41 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ilyang Pharmaceutical Co.,Ltd
665 employees
CEO: Dong-Yeon Kim Headquartered in Yongin, South Korea, Ilyang Pharmaceutical Co.,Ltd is a prominent pharmaceutical enterprise that has been operating since its establishment in 1946. The company, which was formerly known as Il-Yang Pharm. Ind. Co. until ...